|
Synonyms: Jinlitai® | JMT-103 | JMT103
narlumosbart is an approved drug (China (2023))
Compound class:
Antibody
Comment: Narlumosbart (JMT103) is a fully human IgG4κ anti-RANKL (receptor activator of nuclear factor kappa-Β ligand) monoclonal antibody. It blocks the RANK/RANKL protein-protein interaction and thereby reduces pathological osteoclastogenesis in bone cancer.
|
| References |
|
1. Dhillon S. (2024)
Narlumosbart: First Approval. Drugs, 84 (1): 105-109. [PMID:38112898] |
|
2. Liang X, Xue J, Ge X, Li J, Li H, Xue L, Di L, Tang W, Song G, Li Q et al.. (2022)
Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors. Front Oncol, 12: 971594. [PMID:35992822] |
